Genomics

Dataset Information

0

Melanoma cell lines treated with dabrafenib ± trametinib


ABSTRACT: Rapid resistance to BRAF inhibitors in BRAFV600-mutant metastatic melanoma has produced an urgent need for new treatment options. BRAF inhibitor resistance commonly involves reactivation of mitogen-activated protein kinase (MAPK) signaling and yet inhibition of downstream kinases has not circumvented resistance, partly because MAPK is regulated via a complex network of feedback mechanisms that influence pathway rebound. To examine the transcriptome responses of melanoma cells to MAPK inhibition, a panel of 11 BRAFV600-mutant melanoma cell lines were treated with control (DMSO), 100nM dabrafenib alone (i.e BRAF inhibitor monotherapy) or 100nM dabrafenib + 10nM trametinib (i.e combination BRAF + MEK inhibition) for 24h.

ORGANISM(S): Homo sapiens

PROVIDER: GSE98314 | GEO | 2017/09/20

SECONDARY ACCESSION(S): PRJNA384663

REPOSITORIES: GEO

Similar Datasets

| E-GEOD-61992 | biostudies-arrayexpress
| E-GEOD-50509 | biostudies-arrayexpress
2019-07-16 | GSE117666 | GEO
| E-GEOD-44753 | biostudies-arrayexpress
| E-GEOD-64102 | biostudies-arrayexpress
2014-12-03 | GSE61992 | GEO
| PRJEB7503 | ENA
2014-12-12 | GSE64102 | GEO
2022-01-07 | GSE193157 | GEO
2014-02-19 | GSE50509 | GEO